Belinostat
 | |
| Systematic (IUPAC) name | |
|---|---|
|
(2E)-N-Hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide | |
| Clinical data | |
| Trade names | Beleodaq |
| AHFS/Drugs.com | entry |
| Pregnancy category |
|
| Routes of administration | Intravenous (IV) |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 100% (IV) |
| Protein binding | 92.9–95.8%[1] |
| Metabolism | UGT1A1 |
| Excretion | Urine |
| Identifiers | |
| CAS Number |
866323-14-0  |
| ATC code | L01XX49 (WHO) |
| PubChem | CID 6918638 |
| ChemSpider |
5293831  |
| UNII |
F4H96P17NZ |
| ChEBI |
CHEBI:61076 |
| ChEMBL |
CHEMBL408513 |
| Synonyms | PXD101 |
| Chemical data | |
| Formula | C15H14N2O4S |
| Molar mass | 318.348 g/mol |
| |
| |
Belinostat (trade name Beleodaq, previously known as PXD101) is a drug developed by TopoTarget for the treatment of hematological malignancies and solid tumors. It is a histone deacetylase inhibitor.[2]
It was approved in July 2014 by the US FDA to treat peripheral T-cell lymphoma.[3]
In 2007 preliminary results were released from the Phase II clinical trial of intravenous belinostat in combination with carboplatin and paclitaxel for relapsed ovarian cancer.[4] Final results in late 2009 of a phase II trial for T-cell lymphoma were encouraging.[5] Belinostat has been granted orphan drug and fast track designation by the FDA,[6] and was approved in the US for the use against peripheral T-cell lymphoma on 3 July 2014.[3] It is not approved in Europe as of August 2014.[7]
References
- ↑ "Beleodaq (belinostat) For Injection, For Intravenous Administration. Full Prescribing Information" (PDF). Spectrum Pharmaceuticals, Inc. Irvine, CA 92618. Retrieved 21 November 2015.
- ↑ Plumb, Jane A.; Finn, Paul W.; Williams, Robert J.; Bandara, Morwenna J.; Romero, M. Rosario; Watkins, Claire J.; La Thangue, Nicholas B.; Brown, Robert (2003). "Pharmacodynamic Response and Inhibition of Growth of Human Tumor Xenografts by the Novel Histone Deacetylase Inhibitor PXD101". Molecular Cancer Therapeutics 2 (8): 721–728. PMID 12939461.
- 1 2 "FDA approves Beleodaq to treat rare, aggressive form of non-Hodgkin lymphoma". FDA. 3 July 2014.
- ↑ "CuraGen Corporation (CRGN) and TopoTarget A/S Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference". October 2007.
- ↑ Final Results of a Phase II Trial of Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma, December 2009
- ↑ "Spectrum adds to cancer pipeline with $350M deal.". February 2010.
- ↑ H. Spreitzer (4 August 2014). "Neue Wirkstoffe – Belinostat". Österreichische Apothekerzeitung (in German) (16/2014): 27.
| ||||||||||||||||||||||||||||||||||||||